Clinical Trials in the Community
Louise Shiel
CCRE Clinical Trial Centre

- School of Public Health & Preventive Medicine
- Community based Clinical Trials Centre
- Based at Caulfield Hospital >20 yrs
- Links with Alfred Health & GPs
CCRE CTC Research

Investigator Initiated Research
- ASPIVLU - NH&MRC
- AUSPICE - NH&MRC
- HOPE-3 - PHRI, Canada
- INTEGRATE - NH&MRC
- QUARTET - NH&MRC
- SCREEN-HFL - NH&MRC

Coordinating Centre
- ADIPOSE - Cabrini (HREC & Data Management – REDCap)

Industry Sponsored Trials
- Astra Zeneca, Bristol-Myers Squibb, Eli Lily, GSK, Servier
Recruitment & Data Collection
Participant Recruitment

- GP networks
- Volunteer Database
- Health Funds – e.g. BUPA
- Medicare
- Hospital and University newsletters
- Advertising - Local Newspapers, Facebook
- Posters – hospital, libraries
- Clubs – e.g. Rotary, Probus
Participant Visits

- Most of our studies are longitudinal CVD outcome studies with 4 - 10 years follow-up
  - CCRE Clinical Trial Centre (Caulfield Hospital)
  - GP Practices
  - Monash University Peninsula Campus
  - School Rural Health – Shepparton (Melb Uni)
  - Dorevitch Pathology Centres
CCRE CTC

• For Participants
  – Easy access to transport - Bus, Tram, Train
  – Cheap parking - $5 per day / free 2 hr street parking
  – 1800 freecall number
  – Study specific email e.g. med.auspice@monash.edu

• Facilities
  – 4 clinic rooms, 5 Offices & File storage
  – Lab, Alarmed 2x Freezer -80\(^0\text{C}\), Vaccine Fridge
  – Use of Hospital facilities e.g. Linen, Food, Pathology, Cleaning (Sharps disposal) services
Usual Model Data Collection

• Multiple study time points (0, 6, 12, 18 .... etc.)
  – Anthropometric
  – Manual & 24 hour BP, ECG, echocardiography, arterial compliance, body composition
  – Questionnaires – e.g. Exercise, Edinburgh Claudication, SF12, HADS, Food consumption
  – Blood samples stored for biomarker measurement
  – CVD Outcome measures – e.g. hospitalisations, MI, stroke, HF, angina
  – Concomitant Medications
AUSPICE
Australian Study for the Prevention through Immunisation of Cardiovascular Events
Background

• Streptococcus pneumoniae vaccination in animal models shown atherosclerotic plaque
  – Phosphorylcholine lipid antigens in the S.pneumoniae cell wall induce the production of antibodies that cross-react with ox-LDL, a component of atherosclerotic plaques
  – Antibodies then bind to & assist plaque destruction

• Human studies suggest similar mechanisms
  – Possible that pneumococcal vaccination protects against, or even reverses, atherosclerosis

• Sample size based on a 22% RRR
Study Aims

• Whether pneumococcal vaccination decreases the incidence of cardiovascular events
• The mechanism(s) of any effect by testing immunological, genetic, and surrogate markers
• The safety, efficacy, and economic costs of the pneumococcal vaccine considering other health outcomes
Impact

• CVD is still the number one killer in Australia and the potential that pneumococcal vaccination can provide some protection against this is of tremendous public health significance.

• Even if the RRR ~ 22%, this would still represent a similar effect to long-term use of aspirin, beta-blockers, statins, or smoking cessation, all for the one-off cost of a vaccination.

• As the pneumococcal vaccine is already licensed, in use and has a proven safety record, no long lead in phase before translation to clinical use.

• Since only 50% in those over 65 are currently vaccinated, a positive trial might lead to increased vaccine coverage.
AUSPICE Study

• Funded NH&MRC 2014 – 2018 $1,785,279
• Co-ordinated by University of Newcastle
• 6000 participants aged 55-60 to be randomised from 6 sites (Newcastle, Central Coast, Canberra, Perth, Adelaide & Melbourne)
• Outcomes:
  – Followed up using health and death database linkage at 4 yrs for the incidence of major CVD events related to atherosclerosis
**Inclusion/Exclusion Criteria**

### Inclusion criteria:
- Aged between 55 and 60 with at least 2 of:
  - High blood pressure (Dx & Tx)
  - High cholesterol (Dx & Tx)
  - Overweight or obese
    - BMI ≥ 27 or
    - waist circumference (women > 88cm, men > 102cm)

### Exclusion criteria:
- Previously received pneumococcal vaccination
- At higher risk of pneumococcal disease
HRECs for Data Linkage

1. Centre for Health Record Linkage (CHeReL) NSW & ACT
2. Victoria Data Linkage
3. Victorian Cancer Registry
4. SA NT DataLink
5. WA Data Linkage
6. QLD Data Linkage
7. Department of Human Services
8. Australian Institute of Health and Welfare (AIHW)
Linked Data Sets

- Admitted Patient Data Collection
- Emergency Department Data Collection
- State Mortality Data
- Notifiable Infectious Diseases Database
  - related to pneumococcal disease or Influenza only
- Medical Benefits Scheme (MBS)
- Pharmaceuticals Benefits Scheme (PBS)
- National Death Index
- National Cancer Registry data
Recruitment & Visits

• MBS mail-out: age eligibility and postcode only
  – Letter of invitation
  – Screening questionnaire & Reply paid envelope
Or
  – directed to Website to complete questionnaire

• 2 weeks later a reminder letter
Dear First and Last Name,

You’re invited to participate in a new study, the Australian Study for the Prevention through Immunisation of Cardiovascular Events (AUSPICE), which aims to reduce the risk of heart attacks and stroke. Your name has been randomly selected from the Department of Human Services database and we need your help.

Who is doing the research?
This study is a collaborative effort by the University of Newcastle, Australian National University (Canberra), Monash University (Melbourne), Flinders University (Adelaide) and the University of Western Australia (Perth). AUSPICE is publicly funded by the National Health and Medical Research Council. The research team includes clinical specialists from Cardiology, Neurology, Medicine, Public Health, Immunology, Nursing, Pharmacy and Dietetics.

What are we doing?
AUSPICE aims to recruit 6000 men and women aged 55-80 years from around Australia. Half will be given an active vaccine (an existing vaccine originally developed for pneumococcal pneumonia) and the other half will be given a placebo vaccine (saline). Participants will not be told which group they are in. Data from linked hospital and health service records will be used to track cardiovascular and other health events during the 4-5 years after the immunisation is given.

What are we asking you to do?
The trial will only require participants to attend one clinic visit, with a follow-up via SMS or telephone after the immunisation. Participants will be told whether they were given the active vaccine or saline at the conclusion of the study.

Who can participate?
This study is suitable for people who have at least 2 of 3 risk factors for cardiovascular disease, including high blood pressure, high cholesterol and/or being overweight or obese. If you are interested in participating please complete the enclosed ‘Screening Questionnaire’. Participation is voluntary and you can withdraw from the study at any time. For those who are not eligible, we ask that you forward this letter onto a relative or friend who may be eligible to participate.

What next?
If you are interested in participating, please advise the research team by:

- returning the completed Screening Questionnaire using the reply-paid envelope; or
- completing the Screening Questionnaire online: login to

<insert date>

Dear <insert Title and Surname>,

You were recently invited to complete a Screening Questionnaire for AUSPICE, which is a national study aiming to reduce the risk of heart attacks and stroke using a vaccine. Your name was randomly selected from the Department of Human Services database, who have sent this letter on our behalf. The study team do not know who has been contacted and who has not. No personal information has been given out.

This research is conducted by the University of Newcastle, Australian National University (Canberra), Monash University (Melbourne), Flinders University (Adelaide) and the University of Western Australia (Perth), and is publicly funded by the National Health and Medical Research Council.

If you have already responded to the invitation to participate, thank you for your time and contribution. If you have not yet responded, we would be grateful if you would consider completing the Screening Questionnaire and returning it to us in the reply paid envelope previously provided. Alternatively, you can complete the questionnaire online at https://AUSPICE.asco.hmpri.com.au. Participation will contribute to the future prevention of cardiovascular disease. You can also withdraw from the study at any time without hindrance.

If you are not eligible and have passed the invitation onto a family member or friend who may be eligible, thank you. If you have not, we would be grateful if you would consider passing this invitation on to a family member or friend who may be eligible.

Taking part in AUSPICE is purely voluntary. If you do not wish to participate, there is no disadvantage to your future health care and this is the last letter you will receive regarding this study.

If you have any queries or need some assistance, please don’t hesitate to contact your Site Coordinator, 1800 190 108 (tollcall), or email: med.auspice@monash.edu

Professor John Atlia
Professor of Medicine and Epidemiology
Centre for Clinical Epidemiology & Biostatistics
School of Medicine and Public Health
The University of Newcastle

Professor Andrew Tonkin
Head, Cardiovascular Research Unit
School of Public Health and Preventive Medicine
Caulfield Hospital / The Alfred
Monash University

Reminder Letter, Monash Version 3, 17/05/2010
**Questionnaire**

Please complete all of the following questions, unless you are advised to skip ahead to the ‘Next Step’ section of this form on page 5.

Q1 What is your gender? Male ☐ Or Female ☐ (Mark one box only)

Q2 What is your date of birth? _____/_____/_____/ (dd/mm/yyyy)

(Q3) Have you ever been diagnosed or treated for:

<table>
<thead>
<tr>
<th></th>
<th>Yes</th>
<th>No</th>
<th>Unsure</th>
</tr>
</thead>
<tbody>
<tr>
<td>a. High blood pressure (hypertension)</td>
<td>☐</td>
<td>☑</td>
<td>☑</td>
</tr>
<tr>
<td>b. High cholesterol</td>
<td>☑</td>
<td>☐</td>
<td>☑</td>
</tr>
</tbody>
</table>

If ‘No’ to both of these you are ineligible. Skip to the ‘Next Step’ Section of this form.

Q4 Have a doctor ever told you that you are overweight?

[ ] Yes

[ ] No

Please report your height:

[ ] cm / feet & inches

[ ] Use circle correct unit

Please report your weight:

[ ] kgs / stones / pounds

[ ] Use circle correct unit

Please report waist circumference:

[ ] cm / inches

[ ] Use circle correct unit

Q5 Have you ever had?

<table>
<thead>
<tr>
<th></th>
<th>Yes</th>
<th>No</th>
<th>Unsure</th>
</tr>
</thead>
<tbody>
<tr>
<td>a. Adult pneumococcal vaccine (Pneumovax23)</td>
<td>☐</td>
<td>☑</td>
<td>☑</td>
</tr>
<tr>
<td>b. Heart attack (myocardial infarction)</td>
<td>☑</td>
<td>☐</td>
<td>☑</td>
</tr>
<tr>
<td>c. Stroke</td>
<td>☑</td>
<td>☑</td>
<td>☑</td>
</tr>
<tr>
<td>d. Angioplasty, stent, or bypass surgery for your heart or brain</td>
<td>☑</td>
<td>☑</td>
<td>☑</td>
</tr>
<tr>
<td>e. Angioplasty, stent, bypass surgery, or amputation for peripheral vascular disease</td>
<td>☑</td>
<td>☑</td>
<td>☑</td>
</tr>
</tbody>
</table>

Q6 Do you currently have any of the following?

<table>
<thead>
<tr>
<th></th>
<th>Yes</th>
<th>No</th>
<th>Unsure</th>
</tr>
</thead>
<tbody>
<tr>
<td>a. Functional or anatomic ausescia (no functioning spleen)</td>
<td>☑</td>
<td>☑</td>
<td>☑</td>
</tr>
<tr>
<td>b. An immunocompromising condition (e.g. cancer, organ transplant, chronic renal failure, on dialysis, or HIV)</td>
<td>☑</td>
<td>☑</td>
<td>☑</td>
</tr>
<tr>
<td>c. Idiopathic thrombocytopenic purpura (ITP)</td>
<td>☑</td>
<td>☑</td>
<td>☑</td>
</tr>
<tr>
<td>d. Cerebrospinal fluid (CSF) leak</td>
<td>☑</td>
<td>☑</td>
<td>☑</td>
</tr>
<tr>
<td>e. Cochlear implant</td>
<td>☑</td>
<td>☑</td>
<td>☑</td>
</tr>
</tbody>
</table>

Q7 Have you ever been diagnosed or hospitalised with:

<table>
<thead>
<tr>
<th></th>
<th>Yes</th>
<th>No</th>
<th>Unsure</th>
</tr>
</thead>
<tbody>
<tr>
<td>a. COPD</td>
<td>☑</td>
<td>☑</td>
<td>☑</td>
</tr>
<tr>
<td>b. Diabetes</td>
<td>☑</td>
<td>☑</td>
<td>☑</td>
</tr>
<tr>
<td>c. Down syndrome</td>
<td>☑</td>
<td>☑</td>
<td>☑</td>
</tr>
<tr>
<td>d. Alcohol abuse</td>
<td>☑</td>
<td>☑</td>
<td>☑</td>
</tr>
<tr>
<td>e. Chronic liver disease</td>
<td>☑</td>
<td>☑</td>
<td>☑</td>
</tr>
</tbody>
</table>

Q8 Are you a current smoker?

[ ] Yes

[ ] No

If ‘Yes’ to Q5, Q6, Q7 or Q8, you are ineligible. These conditions are associated with an increased risk of Pneumococcal Disease and early vaccination with Pneumovax23 is recommended. See your general practitioner (GP) to discuss receiving the free vaccine. Skip to the ‘Next Step’ section of this form.

Q9 Are you of Aboriginal or Torres Strait Islander origin?

[ ] Yes

[ ] No

If ‘Yes’ to Q9, you are ineligible. Pneumovax23 is recommended for Aboriginal and Torres Strait Islander people over 50 years old. The free vaccine is provided through the Aboriginal Medical Services (AMS) and/or State and Territory immunisation clinics and general practitioners (GP). Skip to the ‘Next Step’ section of this form.

---

Thank You for helping us improve the health of Aust

Date Survey completed...
Are you aged 55 – 60?
Do you suffer from two of the following conditions?

- High cholesterol
- High blood pressure
- Excess bodyweight

We need 6000 Australians to help us change the
Animal and human studies suggest that the pneumococcal vaccine may protect against, or even reverse, a build-up of fatty materials inside the arteries. This build-up can lead to heart attack or stroke. You have the opportunity to participate in a world-first study to determine whether the pneumococcal vaccine reduces the risk of heart attack and stroke.

Half the participants will be given the pneumococcal vaccine (an existing vaccine originally developed for pneumococcal pneumonia) and the other half will be given a placebo vaccine (saline). Patients won’t be told which group they are in, and data from their health records will be used to track cardiovascular and other health.
# AUSPICE Contacts

[Website Screenshot]

## Contact

### Newcastle
- **Site Lead:** Professor John Attia  
  Immunisers: Roseanne Peel  
  [auspice@newcastle.edu.au](mailto:auspice@newcastle.edu.au)  
  Ph: (02) 4042 0523

### Canberra
- **Site Lead:** Professor Walter Abhayaratna  
  Immuniser: Judith Ingversen  
  [Judith.Ingversen@act.gov.au](mailto:Judith.Ingversen@act.gov.au)  
  Ph: (02) 6244 4108

### Melbourne
- **Site Lead:** Professor Andrew Tonkin  
  Immuniser: Caroline Steer  
  [med.auspice@monash.edu](mailto:med.auspice@monash.edu)  
  Ph: 1800 199 108

### Adelaide
- **Site Lead:** Professor Derek Chew  
  [HSR@ahmri.com](mailto:HSR@ahmri.com)  
  Ph: 1300 725 272

### Perth
- **Site Lead:** Professor Joseph Hung  
  Immuniser: Michelle Blackwood  
  [michelle.blackwood@liwa.uwa.edu.au](mailto:michelle.blackwood@liwa.uwa.edu.au)  
  Ph: (08) 6457 3198

[Consent File]  
[Information Statement]
High blood pressure
· Excess bodyweight

We need 6000 Australians to help us change the health of a nation and test whether a safe, existing vaccine can reduce the risk of heart disease.

Project Information

Date of Birth: 1959 - November - 18
Postcode: 3162

I am Male  I am Female
Auspice Website - Screening

Questionnaire Progress
Page 1 of 4

Q1. Have you ever been diagnosed or treated for:

a. High blood pressure (hypertension)  
   Yes  No  Unsure

b. High cholesterol  
   Yes  No  Unsure
Questionnaire Progress

Page 2 of 4

Q2 Measures

a. Has a doctor ever told you that you are overweight?
   - Yes
   - No
   - Unsure

Choose which units you prefer:
- Metric
- Imperial

b. Please report your height (cm or feet/inches)
   - cm

c. Please report your weight (kg or stones/pounds)
   - kgs

d. Please report your waist circumference
   - cm

View Waist Measurement Guide

Next >>
Auspice Website - Screening

Questionnaire Progress

Page 3 of 4

Q3. Have you ever had?

a. Adult pneumococcal vaccine (Pneumovax23)
   - Yes
   - No
   - Unsure

b. Heart attack (myocardial infarction)
   - Yes
   - No
   - Unsure

c. Stroke
   - Yes
   - No
   - Unsure

d. Angioplasty, stent, or bypass surgery for your heart or brain
   - Yes
   - No
   - Unsure

e. Angioplasty, stent, bypass surgery, or amputation for peripheral vascular disease
   - Yes
   - No
   - Unsure

Q4. Do you currently have any of the following?

a. Functional or anatomic asplenia (no functioning spleen)
   - Yes
   - No
   - Unsure

b. An immunocompromising condition
   (e.g. cancer, organ transplant, chronic renal failure, kidney dialysis, or HIV)
   - Yes
   - No
   - Unsure

c. Idiopathic thrombocytopenic purpura (ITP)
   - Yes
   - No
   - Unsure

d. Cerebrospinal fluid (CSF) leak
   - Yes
   - No
   - Unsure
## AUSPICE Website – Site View

### Screening - Online Responses

<table>
<thead>
<tr>
<th>Screening Date</th>
<th>Screening Code</th>
<th>Eligibility Status</th>
<th>1a/1b/BMI/WC (Age)</th>
<th>Response</th>
<th>Status</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>12/08/2016</td>
<td>MEL7265</td>
<td>Eligible</td>
<td>Y / Y / 28 / 88cm [M] (58y)</td>
<td>Yes</td>
<td>Processed</td>
<td>New Booking</td>
</tr>
<tr>
<td>13/09/2016</td>
<td>MEL9750</td>
<td>Eligible</td>
<td>N / Y / 30 / 110cm [M] (60y)</td>
<td>Yes</td>
<td>Processed</td>
<td>New Booking</td>
</tr>
<tr>
<td>16/12/2016</td>
<td>MEL13064</td>
<td>Unknown</td>
<td>Y / N / 31 / - (58y)</td>
<td>Yes</td>
<td>New</td>
<td>Validate</td>
</tr>
<tr>
<td>24/02/2017</td>
<td>MEL13728</td>
<td>Eligible</td>
<td>Y / Y / - - (60y)</td>
<td>Yes</td>
<td>Processed</td>
<td>New Booking</td>
</tr>
<tr>
<td>24/02/2017</td>
<td>MEL13737</td>
<td>Eligible</td>
<td>Y / Y / 24 / 80cm [F] (58y)</td>
<td>Yes</td>
<td>Processed</td>
<td>New Booking</td>
</tr>
<tr>
<td>24/02/2017</td>
<td>MEL13746</td>
<td>Eligible</td>
<td>Y / N / 29 / - (58y)</td>
<td>Yes</td>
<td>Processed</td>
<td>New Booking</td>
</tr>
<tr>
<td>1/03/2017</td>
<td>MEL13770</td>
<td>Eligible</td>
<td>N / Y / 27 / - (55y)</td>
<td>Yes</td>
<td>Processed</td>
<td>New Booking</td>
</tr>
<tr>
<td>24/02/2017</td>
<td>MEL13912</td>
<td>Eligible</td>
<td>Y / Y / - - (56y)</td>
<td>Yes</td>
<td>Processed</td>
<td>New Booking</td>
</tr>
<tr>
<td>27/02/2017</td>
<td>MEL13814</td>
<td>Eligible</td>
<td>Y / Y / 37 / - (60y)</td>
<td>Yes</td>
<td>Processed</td>
<td>New Booking</td>
</tr>
<tr>
<td>22/03/2017</td>
<td>MEL14114</td>
<td>Eligible</td>
<td>Y / Y / 14 / 114cm [F] (58y)</td>
<td>Yes</td>
<td>New</td>
<td>Process</td>
</tr>
</tbody>
</table>
Study Process

• Site staff confirm eligibility & book 45 min visit
• Visit: Informed Consent
• Demographics
• Height, Weight, Waist circumference, BP, HR
• Medical Hx, Medications,
• Randomise to Pneumonovax or placebo
• Follow-up at 7 & 28 days to identify any adverse reactions via Vaxtracker
Vaxtracker

• Web-based system to collect AE
• Messages sent after vaccination asking participants to complete survey
• Embedded link directs the participant to online questionnaire
  – collects information on symptoms experienced & medical assistance
• Automatic notification to study site staff of a participant with a “Serious Symptom”
  – i.e. major swelling from elbow to shoulder joint, hospitalization
Figure one: AUSPICE Vaxtracker Survey process

Vaccination date at Study Centre: participant records (name/DOB, contact details) are uploaded from AUSPICE database into Vaxtracker.

Day 1: A Vaxtracker welcome message is sent to participants (mobile no./email provided) or study site staff (land line number only). Nil response required.

Day 7: A message with a link to the main survey is sent to the study participant or to study site. When only a landline phone number is given, study site staff will interview and enter the participant’s information onto Vaxtracker.

Day 28: A message with a link to the final survey is sent to the study participant or study site. When only a landline phone number is given, study site staff will interview and enter the participant’s information onto Vaxtracker.

Nil response after 3 days? Two reminder messages are sent to the participant or to study site staff, three days apart.
## Study Timelines

<table>
<thead>
<tr>
<th>Expected Milestones</th>
<th>Commence</th>
<th>Complete</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ethics and data linkage approvals</td>
<td>Jan 2014</td>
<td>Dec 2014</td>
</tr>
<tr>
<td>Recruitment and randomisation</td>
<td>Jan 2015</td>
<td>Dec 2015</td>
</tr>
</tbody>
</table>

*Start-up meeting Feb 2015*

<table>
<thead>
<tr>
<th>Revised Milestones</th>
<th>Commence</th>
<th>Complete</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ethics and data linkage approvals</td>
<td>Jan 2014</td>
<td>Dec 2015</td>
</tr>
<tr>
<td>Recruitment and randomisation</td>
<td>Jan 2016</td>
<td>Dec 2017</td>
</tr>
</tbody>
</table>

First Medicare mail-out February **2016**
Medicare Mail-outs

• Initially estimated to send 60,000 letters of invitation to randomise 6,000 required for study
  – Send 60,000 letters initially or in batches?
  – Decided on 4 mail-outs (2500 letters x 6 sites x 4)
  – Areas within 25km of site
  – Cost blow-outs
    • After first responses decided to send 5000 per site
      – $75,000/mail-out to 5000 per site
    • Jan 2016 postage costs increased
    • Extra 2 un-planned mail-outs for 2017 (May and July)
DHS area mail-out
Slow recruitment

• Only ~ 2760/6000 recruited by Dec 2016
• 2017 Plan
• Open up recruitment to volunteers
  – Ask those who received a letter but are ineligible to pass on the information to friends/relatives
• Advertising
  – Posters / Local Papers / Facebook
• 2 x Further mail-outs
Media Release

New research asks whether vaccination can prevent heart attacks and strokes for those at risk

A major national Monash University collaboration is now testing whether a safe, one-off vaccine can help to reduce the risk of heart attacks and strokes.

The Australian Study for the Prevention through Immunisation of Cardiovascular Events (ASPIRE) team is inviting people aged 55 - 60 who suffer from two of the conditions of high cholesterol, high blood pressure or excess bodyweight to trial the vaccine at health services across Australia.

Pneumococcal vaccine may provide 'amazing' outcome in prevention of stroke, heart attack

Posted Wed 31 Aug 2016, 6:37am

Australian researchers are recruiting participants for a trial to see whether the pneumococcal vaccine can reduce the risk of heart attacks and stroke by up to 20 per cent.

Cardiovascular disease is still the number one killer of Australians, and at-risk patients take statins, beta blockers and aspirin on a daily basis to help reduce the risk of heart attack and stroke.

But one cheap, readily-available vaccine may provide the same benefit.
CCRE CTC AUSPICE Recruitment

- Forms returned via mail 1296
- **Forms completed online 356**
- Interested 730
- Future appointments booked 76
- Randomised 460 (Male 253 & Female 207)
  - Highest recruiting area
    - Chelsea/Parkdale
    - Blackburn
    - Malvern
    - Ivanhoe
Challenges

• Staff employment
  – Projected start 2015 but 1st enrolment Feb 2016

• Staffing qualifications
  – Immunisation nurse

• Study Age group – still working full-time

• 25 km from study centre but potentially > 2 hours travel

• Areas to target for recruitment (Wodonga – Morwell - Sydney)
More information

• Website: https://auspice.apps.hmri.com.au/
• Phone: 1800 199 108
• Email: med.auspice@monash.edu